HR 6807 United States House · 118th Congress

KO Cancer Act

This bill increases funding for cancer research by directing an additional 25% of the 2022 National Cancer Institute (NCI) budget annually through 2028. It also requires the Health and Human Services Secretary to study the causes of cancer drug shortages - including supply chain issues, FDA approval delays, and lack of generic drugs - and submit a report with solutions to Congress within one year. The key provisions directly affect NCI-funded research programs and aim to improve cancer drug availability for patients and healthcare providers. The bill focuses on concrete policy changes: boosting research funding and mandating a systematic review of drug shortages, without advocating for specific outcomes.

Bill status in committee 1 of 4 stages cleared

Introduction

Dec 2023

Committee Review

Floor Vote

President

Introduced Dec 14, 2023 Last action Dec 15, 2023

Floor votes

How they voted

No floor votes recorded yet.

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Dec 15, 2023

Committee

Referred to the Subcommittee on Health.

lower

Dec 14, 2023

Committee

Referred to the Committee on Appropriations, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

lower

Dec 14, 2023

Introduced

Introduced in House

lower

1 primary · 3 co-sponsors